Monopar de­lays IPO again de­spite slash­ing of­fer­ing while a mi­cro-cap biotech clinch­es $9M

Two low-pro­file bud­get biotechs have be­come the lat­est ca­su­al­ty of a weak IPO mar­ket. Monopar Ther­a­peu­tics is post­pon­ing its pub­lic de­but for a sec­ond time …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER